36 results about "Globin" patented technology

The invention discloses a blood protein precise active peptide capable of tonifying qi and blood, improving microcirculation and promoting vasodilation and a preparation method and application thereof, and belongs to the technical field of blood protein peptide. The blood protein precision active peptide comprises at least one of LGFP, IGFP, FPHFN, LFL, LFI, FESF, ILF, LIF, FLL, FIL, FII or FPHFD. The prepared blood protein precision active peptide has multiple biological activities: an antihypertensive effect is achieved by inhibiting ACE and vasoconstriction substances; vasodilation is promoted by activating a PI3K / AKT / eNOS signal channel; a zebra fish model proves that the traditional Chinese medicine composition has the effects of remarkably improving microcirculation and tonifying qi and blood. The preparation method is low in equipment requirement, simple in process, easy to operate and convenient for industrial large-scale production. The method enriches a bioactive peptide library, and is of great significance in promoting technical progress and industrial upgrading in the field of hemoglobulin peptides.

The invention provides application of pinostrobin in preparation of a medicine for treating gastric ulcer, and belongs to the technical field of biological medicine. The pinostrobin provided by the invention realizes the anti-gastric ulcer effect by improving the gastric mucosa blood flow volume, inhibiting inflammatory reaction, inhibiting oxidation reaction and maintaining the integrity of the gastric mucus barrier. Pinostrobin can reduce the gastric ulcer area of rats and increase the pain threshold value; the content of ET-1 in plasma is reduced, and the repairing effect of gastric mucosa is enhanced; the contents of TNF-alpha and IL-6 are reduced, the content of IL-10 is increased, and the anti-inflammatory effect is enhanced; the content of T-SOD in plasma is increased, the content of MPO is reduced, and the antioxidant effect is enhanced. The pinostrobin is expected to be used as a new medicine for treating gastric ulcer.

The present invention concerns the use of a molecule chosen from a globin, a globin protomer or an extracellular hemoglobin of Annelids, for treating and / or preventing at least one complement-activation associated disease, preferably ischemia / reperfusion injury and / or transplant rejection.

This invention provides compounds for the treatment, prevention, or suppression of various pathological conditions (such as proliferative disorders like cancer, β-globin disorders, fibrosis, pain, neurodegenerative diseases, Prader-Willi syndrome, malaria, viral infections, myopathy, and autism) by inhibiting G9a. [Solution] The following general formula (I) TIFF2026062914000401.tif2449 A compound represented by or a pharmacoposly acceptable salt thereof is provided.

The invention relates to the technical field of animal breeding, in particular to a method for breeding black sheep. The method comprises the following steps: introducing an expression cassette into a cell to obtain a transgenic cell; and carrying out somatic cell nuclear transplantation cloning by adopting the transgenic cells to obtain the black sheep. The expression cassette comprises an intron of PK5 and beta-globin, and an EDN3 gene, the PK5 comprises a nucleotide sequence as shown in SEQ ID NO. 2; and the EDN3 gene comprises a nucleotide sequence as shown in SEQ ID NO. 4. A specific expression cassette and a carrier are researched, the black sheep of which the skin, hair, tongue, oral mucosa, eye white mucosa, epididymis and ears all become black can be prepared through somatic cell cloning on the basis of cells edited by the carrier, and important application value and economic value are achieved.

This invention provides a high-recovery heme iron extraction method and apparatus using enzymatic hydrolysis-multi-stage centrifugal coupling, relating to the fields of biopharmaceuticals and fluid dynamics processing technology. The method first constructs a polyanionic electrolyte shielding system, utilizing electrostatic potential energy to induce conformational instability of globin and pre-exposure of hydrophobic cavities, reducing binding energy at the molecular level and solving the problem of heme's encapsulation resistance in high-concentration systems. Then, high-shear coupled enzymatic hydrolysis is performed within a micron-sized liquid film generated by a hypergravity field, utilizing the instantaneous synergy of mechanical shear stress and enzymatic degradation to achieve directional exfoliation of heme, eliminating secondary re-adhesion effects. Finally, directional phase transition regulation is performed based on density gradient drive, and a high-frequency pulsed pressure field is introduced for in-situ exchange washing, distinguishing and retaining impurities and crystal cores, outputting a high-purity, flavor-neutral heme iron product. This invention effectively improves the controllability of the extraction process and the stability of industrial continuous production.

This application discloses a precise active peptide of hemoglobin with the functions of replenishing qi and blood, improving microcirculation, and promoting vasodilation, as well as its preparation method and application, belonging to the field of hemoglobin peptide technology. The precise active peptide of hemoglobin contains at least one of LGFP, IGFP, FPHFN, LFL, LFI, FESF, ILF, LIF, FLL, FIL, FII, or FPHFD. The prepared precise active peptide of hemoglobin exhibits multiple biological activities: it exerts a hypotensive effect by inhibiting ACE and vasoconstrictive substances; it promotes vasodilation by activating the PI3K / AKT / eNOS signaling pathway; and it has been shown to significantly improve microcirculation and replenish qi and blood in a zebrafish model. The preparation method has low equipment requirements, is simple and easy to operate, and is suitable for large-scale industrial production. This invention enriches the bioactive peptide library and is of great significance for promoting technological progress and industrial upgrading in the field of hemoglobin peptides.

The invention relates to the technical field of biology, in particular to recombinant spider silk protein, modified polyurethane and application of the recombinant spider silk protein and the modified polyurethane. The recombinant spider silk protein provided by the invention comprises spider silk protein or spider silk-like protein; the spider silk protein or spider silk-like protein comprises at least one spider silk globulin NT, at least one spider silk protein repeat region and at least one spider silk globulin CT from the N end to the C end. Research finds that when the recombinant spider silk protein is applied to waterborne polyurethane, the mechanical strength of a polyurethane material is remarkably improved, the mechanical property of the polyurethane material is enhanced, and the polyurethane material is environmentally friendly and non-toxic, has the characteristics of no toxicity, high strength, high elasticity and the like, and keeps the original characteristics of low organic matter emission, no pollution, high elasticity, air permeability and the like at the same time. The recombinant spider silk protein can have a CBM structure, so that the mechanical property can be improved. Fluorescent protein and / or chromoprotein can be fused on the recombinant spider silk protein, polyurethane with different appearances can be obtained, and color combination is firm.

The invention discloses a DNA (Deoxyribonucleic Acid) molecule for promoting mRNA (Messenger Ribonucleic Acid) expression and 3'UTR (Untranslated Region) in the mRNA molecule obtained by transcription of the DNA molecule, and the DNA molecule is derived from COX7B of a cytochrome C oxidase family. The invention also discloses an application of the composition containing the 3 'UTR in preparation of RNA (Ribonucleic Acid) therapeutic drugs or mRNA (Messenger Ribonucleic Acid) vaccines. Compared with a control group alpha-globin, the insertion of the 3'UTR fragment provided by the invention has the advantages that the expression quantity of renilla luciferase in Lent-X 293T cells is increased by 2.03 times, and the expression quantity of renilla luciferase in HeLa cells is increased by 3.62 times. The invention shows that the 3 'UTR has an excellent prospect of being applied to RNA (Ribonucleic Acid) therapeutic drugs or mRNA vaccines.

The invention discloses an image processing method and device for judging suspension red blood cell hemolysis. The method comprises the following steps: acquiring a blood image set; the blood image set comprises a plurality of blood images and corresponding label information; acquiring a blood parameter information set; the blood parameter information set comprises a plurality of blood parameters and corresponding label information; the blood parameters comprise hemoglobin concentration, reticulocyte concentration, indirect bilirubin concentration, lactic dehydrogenase concentration and globin concentration; utilizing the blood image set and the blood parameter information set to construct a blood hemolysis composite detection model; based on the blood hemolysis composite detection model, processing the collected blood image and blood parameters to obtain hemolysis detection result information; the hemolysis detection result information is used for representing erythrocyte hemolysis information of the blood corresponding to the collected blood image and blood parameters.

According to the present disclosure, a simple and accurate method for quantifying ergothioneine in a sample containing globin protein can be provided. A method for quantifying ergothioneine in a collected sample, comprising: (A) heating the sample; (B) mixing the heated sample with trichloroacetic acid; and (C) subjecting the sample obtained in step (B) to a quantitative operation; A method comprising:

To provide a composition that can improve the quality of sleep. [Solution] A composition for improving sleep quality containing globin protein hydrolysate.

Here, the inventors developed a strategy to modify the chromatin status of HSPCs at the HBG promoters to reactivate HbF expression. In particular, the inventors used from 1 to 4 single guide RNA (sgRNA) molecules spanning from the -220 to the -20 region of the HBG promoters together with CRISPR-based epigenome editors, namely dCas9-CBPcore and Tet1-dCas9. The first editor is capable of inserting histone acetylation while the second editor is performing DNA demethylation. Both epigenetic marks are associated with active transcription and are present in fetal erythroid cells expressing HbF. This strategy allows the ex vivo modification of adult HSCs to recreate a fetal-like epigenetic context leading to HbF production. Moreover, it avoids the genotoxicity associated with classical genome editing tools relying on DNA cleavage. Thus, the present invention relates to a method of increasing the expression of gamma globin in a population of eukaryotic cells through epigenome editing.

In certain embodiments a lentiviral vector for the treatment of sickle cell disease (SCD) is provided. In certain embodiments the vector comprises an expression cassette that encodes that an anti-sickling β-globin gene and an shRNA that inhibits expression of a BCL11A gene (BCL11A shRNA) wherein said expression cassette is in reverse orientation in the vector; a β-globin locus control region (LCR) comprising a reduced length hypersensitive site 1 (HS1) sequence, a reduced length hypersensitive site 2 (HS2) sequence, a reduced length hypersensitive site 3 (HS3) sequence, and a reduced length hypersensitive site 4 (HS4) sequence, where said anti-sickling β-globin gene is operably linked to the human β-globin locus control region;.

The invention discloses a DNA (Deoxyribonucleic Acid) molecule for promoting mRNA (Messenger Ribonucleic Acid) expression and 3'UTR (Untranslated Region) in the mRNA molecule obtained by transcription of the DNA molecule, and the DNA molecule is derived from a COX17 gene of a cytochrome C oxidase family. The invention also discloses an application of the composition containing the 3 'UTR in preparation of RNA (Ribonucleic Acid) therapeutic drugs or mRNA (Messenger Ribonucleic Acid) vaccines. Compared with a control group alpha-globin, the insertion of the 3 'UTR fragment provided by the invention enables the expression quantity of renilla luciferase in LentiX 293T cells to be increased by 2.76 times and the expression quantity of renilla luciferase in HeLa cells to be increased by 6.41 times, and shows that the 3' UTR has an excellent prospect of being applied to RNA (Ribonucleic Acid) therapeutic drugs or mRNA (Messenger Ribonucleic Acid) vaccines.

Provided is a method of treating or alleviating one or more pathologies associated with β- thalassemia in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising an effective amount of an anti-matriptase-2 antibody or antigen-binding fragment thereof. The one or more pathologies may be insoluble liver iron stores: α-globin precipitates in ery throid cells; reactive oxidized species formation; apoptosis of erythroid cells; reticulocytosis; or a combination thereof.

The invention provides a UTR element HBB-G and a construction method and application thereof, and relates to the technical field of mRNA. According to the present invention, ribosome load prediction and secondary structure optimization are performed on the 5 'UTR of Homo sapiens haplotype T7 delta-globin (the NCBI number is AF339412.1) through the PadleHelix platform, and the obtained optimized sequence avoids the inhibitory hairpin structure, such that the luciferase expression quantity is significantly improved compared with the natural UTR. On the basis of an optimized sequence, an ncRNA sequence without a secondary structure is introduced, translation inhibition of a 5 'cap region is further relieved, and a constructed HBB-G mutant (the DNA sequence of HBB-G is as shown in SEQ NO.1, and the RNA sequence is as shown in SEQ NO.2) enables the protein expression quantity to be further improved.

The invention relates to application of a compound DMT207 in preparation of a medicine for treating beta-globin disease, and belongs to the technical field of biological medicine. The invention finds that the compound DMT207 shows the characteristic that the toxicity in a red progenitor cell line (HUDEP)-2 and a human primary hematopoietic stem cell is lower than that of decitabine, and can induce high expression of fetal hemoglobin under the condition of maintaining healthy cell activity, and the induction effect of the compound DMT207 is far higher than that of decitabine. In a beta-thalassemia model mouse, the compound DMT207 can activate fetal hemoglobin expression, relieve spleen swelling, promote erythrocyte maturation and relieve the beta-thalassemia symptom on the premise of not influencing the body weight. Therefore, compared with an existing beta-globin disease treatment product, the compound DMT207 is good in specificity, free of DNA damage, small in toxicity and wide in application prospect.

The invention relates to the technical field of biological medicine, and discloses a method for constructing a Myh6-CRE transgenic golden hamster model and application of the Myh6-CRE transgenic golden hamster model. The invention provides a specific DNA (deoxyribonucleic acid) molecule. The specific DNA molecule sequentially comprises an upstream insulator, a Myh6 promoter, a Cre recombinase coding gene, a beta-globin polyA and a downstream insulator from upstream to downstream. The invention also provides a method for preparing the transgenic golden hamster, which comprises the following steps: introducing the expression construct containing the specific DNA molecule into a golden hamster fertilized egg in a fertilized egg microinjection manner, and randomly integrating the expression construct into a golden hamster genome, thereby obtaining the transgenic golden hamster. The invention further provides a Myh6-CRE transgenic golden hamster model, the transgenic golden hamster expresses Cre recombinase under the driving of a Myh6 promoter, and specific recombination between LoxP sites can be mediated. The Myh6-CRE golden hamster constructed by the invention can be used for establishing a conditional gene knockout model, and is suitable for researching the function and action mechanism of the Myh6 related gene in the occurrence and development process of heart and related diseases.

The application discloses a quality control method and device for clinical detection samples, electronic equipment and a storage medium, and belongs to the technical field of high-throughput sequencing technology. The quality control method for the clinical detection samples comprises the following steps: performing quality control filtering on an original FASTQ data file to obtain a target FASTQ data file; performing alignment on the target FASTQ data file and a reference genome sequence file to obtain a BAM file; determining an alignment rate, rRNA content and globin RNA content according to the BAM file; performing sequencing depth detection by using the BAM file to obtain gene 3' end sequencing depth and gene 5' end sequencing depth; performing consistency checking on multiple sequencing data obtained by using multiple sequencing strategies on the clinical detection samples to obtain a consistency checking result; and comprehensively judging whether the clinical detection samples are qualified. The application can accurately detect the quality of the clinical detection samples and improve the effectiveness of the data.

The invention discloses an anti-zeta globin antibody and application thereof, and relates to the field of antibodies. The anti-zeta globin antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for zeta globin detection, and has good activity and specificity.

The present invention is characterized by compositions and methods for editing harmful mutations associated with heme disorders such as sickle cell disease (SCD). In a particular embodiment, the present invention provides a method for correcting mutations in β-globin polynucleotides using a modified adenosine base editor called “ABE8” with unprecedented levels of efficiency (e.g., >60 to 70%).

Enhancing fetal hemoglobin (HbF) production through targeted promoter editing using base editing technologies. An embodiment includes a composition for enhancing fetal hemoglobin (HbF) expression in mammalian cells, the composition comprising a base editing system comprising at least two guide RNAs comprising targeting sequences selected from SEQ ID NO: 1 to SEQ ID NO: 5. Specifically, it involves the design and use of single guide RNAs (sgRNAs) targeting key regulatory elements within the gamma-globin (HBG1 / 2) promoter. The method combines the use of adenosine base editors to introduce mutations, creating new binding sites for transcriptional activators like TAL1 and KLF1, and disrupting repressor binding sites such as BCL11A and ZBTB7A / LRF. This dual-targeting approach significantly increases HbF expression, offering a potential therapeutic strategy for treating beta-hemoglobinopathies like sickle cell disease and beta-thalassemia.

In certain embodiments a lentiviral vector having an LCR comprising HS1 ENCODE core (EC1) sequence (SEQ ID NO:1), and one or more of an HS2 core sequence (ecHS2), an HS3 core sequence (ecHS3), an HS4 core sequence (ecHS4), a full length HS2, a full length HS3, and / or a full length HS4 sequence is provided. In certain embodiments the vector comprises a modified βAS3-globin transgene, where transgene comprises a codon optimized exon 1, and / or a codon optimized exon 2, and / or a codon optimized exon 3.

The present application belongs to the technical field of pharmaceutical preparations, and particularly relates to application of cellular globin in preparation of a medicine for preventing and / or treating diabetes. The present application uses cellular globin for treating diabetes, especially type II diabetes. In the case of persistent hyperglycemia of diabetes, the content of cellular globin is increased to effectively eliminate the oxidative damage of various sugar metabolism byproducts to the body in various tissues and organs of the body, thereby slowing down the occurrence and development of complications caused by diabetes, which is specifically manifested in: reducing the content of blood sugar; reducing the content of total cholesterol; reducing the content of triglyceride; reducing the level of low-density lipoprotein; improving and restoring the normal morphological structure of pancreatic tissue; promoting the proliferation of islet beta cells; and promoting the secretion of insulin and glucagon of islets. In summary, the cellular globin can be used for treating diabetes.

The invention provides an electrochemical biosensor for detecting IgG in blood and a construction method thereof, and belongs to the technical field of electrochemical biosensors, and the construction method comprises the following steps: mixing aniline, perchloric acid and water, adding polystyrolsulfon acid to obtain an electro-deposition solution, then immersing a glassy carbon electrode into the electro-deposition solution, and carrying out ultrasonic treatment; a polyaniline / glassy carbon electrode is obtained through chronopotentiometry electro-deposition; chloroauric acid trihydrate, sodium chloride and water are mixed to obtain a mixed aqueous solution, the polyaniline / glassy carbon electrode is immersed in the mixed aqueous solution, a gold nanoparticle / polyaniline / glassy carbon electrode is obtained through cyclic voltammetry electrodeposition, a lasso peptide solution is dropwise added to the working surface of the gold nanoparticle / polyaniline / glassy carbon electrode for incubation, and the lasso peptide / gold nanoparticle / polyaniline / glassy carbon electrode is obtained. And constructing to obtain the electrochemical biosensor. By means of the overall hydrophilicity and electric neutrality of the polypeptide, non-specific protein adsorption can be effectively resisted, the detection sensitivity and accuracy are improved, and ultra-low pollution immunoglobulin G detection in blood is achieved.

The present application relates to synthetic MAR fragments, expression vectors, expression systems and their applications, and belongs to the field of biotechnology. The novel synthetic MAR fragments are MAR-1, MAR-2 and MAR-3. The MAR fragments of the present application are designed and synthesized based on the common sequence characteristics of beta-globin MAR sequence, X-29 sequence, beta-interferon MAR sequence and MAR 1-68 sequence. It is found that when MAR-1, MAR-2 and MAR-3 are used simultaneously for the expression of exogenous proteins in CHO cells, the effect of MAR-1 is the best. The expression amount of exogenous proteins can be increased by 5.04-5.47 times compared with the system without MAR fragments. More preferably, the 8-copy tandem repeat sub-DNA fragment composed of MAR-1 fragment has better ability to increase the expression amount.

1. The name of the design product: packaging bottle (IG golden globin protein factor). 2. The use of the design product: used for filling health and nutritional diet products. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

The invention belongs to the field of biological medicine, and relates to a preparation method of a high-expression humanized ACE2 animal mouse model. The invention provides a vector. The vector sequentially comprises a 5'homologous arm segment, a human ACE2 gene segment, a WPRE segment, a beta-globin segment, a pA segment, a PGK-Puro segment and a 3 'homologous arm segment from a 5' homologous arm to a 3 'homologous arm. The vector obtained by the invention is a targeting vector and can be used for preparing a high-expression humanized ACE2 animal mouse model.

The application discloses an image processing method and device for judging hemolysis of suspended red blood cells, and the method comprises the following steps: acquiring a blood image set; the blood image set comprises a plurality of blood images and corresponding label information; acquiring a blood parameter information set; the blood parameter information set comprises a plurality of blood parameters and corresponding label information; the blood parameters comprise hemoglobin concentration, reticulocyte concentration, indirect bilirubin concentration, lactate dehydrogenase concentration and globin concentration; a blood hemolysis composite detection model is constructed by using the blood image set and the blood parameter information set; the collected blood image and blood parameter are processed based on the blood hemolysis composite detection model, and hemolysis detection result information is obtained; the hemolysis detection result information is used for representing the red blood cell hemolysis information of the corresponding blood of the collected blood image and blood parameter.